(Q41948234)

14 October 2017

Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy (English)

1 reference

14 October 2017

chronic myeloid leukemia

0 references

2

Hagop Kantarjian

1 reference

14 October 2017

5

Zeev Estrov

1 reference

14 October 2017

9

Jorge Cortes

1 reference

14 October 2017

4

Susan O'Brien

1 reference

14 October 2017

8

Gautam Borthakur

1 reference

14 October 2017

Guillermo Garcia-Manero

series ordinal

6

object named as

Guillermo Garcia-Manero

1 reference

14 October 2017

3

Jianqin Shan

1 reference

14 October 2017

1

Dushyant Verma

1 reference

14 October 2017

Charles Koller

7

1 reference

14 October 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

14 October 2017

1 reference

14 October 2017

116

1 reference

14 October 2017

11

1 reference

14 October 2017

2673-2681

1 reference

Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Chronic myeloid leukemia: diagnosis and treatment

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Clonal evolution in chronic myelogenous leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Characteristics of accelerated disease in chronic myelogenous leukemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4216809

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

2 December 2018

1 reference

12 December 2020

Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure

1 reference

12 December 2020

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

1 reference

12 December 2020

The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia

1 reference

12 December 2020

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia

1 reference

12 December 2020

Nonparametric Estimation from Incomplete Observations

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.25015

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCR.25015

1 reference

14 October 2017

1 reference

14 October 2017

PubMed publication ID

20499401

1 reference